Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug targets hard-to-treat cancers with missing MTAP gene

NCT ID NCT05245500

Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 03, 2026 · Updated 2 times

Summary

This early-stage trial tests an experimental drug called MRTX1719 in adults with advanced solid tumors that have a missing MTAP gene. The study aims to find a safe dose and see if the drug can shrink tumors or slow their growth. About 336 participants with cancers like mesothelioma, lung cancer, or pancreatic cancer will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 336 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2022

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Histologically confirmed diagnosis of a solid tumor malignancy with homozygous deletion of the MTAP gene detected in tumor tissue. * Unresectable or metastatic disease. * Presence of a tumor lesion amenable to mandatory biopsy for pharmacodynamic evaluation at baseline and on-study unless Sponsor-confirmed as medically unsafe or infeasible. * Age ≥ 18 years. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Adequate organ function. Exclusion Criteria * Prior treatment with a PRMT5 or MAT2A inhibitor therapy. * Active brain metastases or carcinomatous meningitis. * History of significant hemoptysis or hemorrhage within 4 weeks of the first dose of study treatment. * Major surgery within 4 weeks of first dose of study treatment. * History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions (eg, uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study treatment or result in inability to swallow oral medications. * Cardiac abnormalities. * Other protocol-defined Inclusion/Exclusion criteria apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced solid tumor are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant peripheral nerve sheath tumor mesothelioma neoplasm neurofibrosarcoma non-small cell lung carcinoma pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced solid tumor Malignant peripheral nerve sheath tumors Mesothelioma Non small cell lung cancer Pancreatic adenocarcinoma Solid tumor

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    22 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cancer and Hematology Centers of Western Michigan

    RECRUITING

    Norton Shores, Michigan, 49444, United States

  • Dana-Farber Cancer Institute

    RECRUITING

    Brookline, Massachusetts, 02251, United States

  • David H Koch, Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10021, United States

  • Local Institution - 108

    COMPLETED

    Milwaukee, Wisconsin, 53226, United States

  • Local Institution - 124

    WITHDRAWN

    Chicago, Illinois, 60637, United States

  • Local Institution - 134

    WITHDRAWN

    Seattle, Washington, 98109, United States

  • MDACC

    RECRUITING

    Houston, Texas, 77030, United States

  • Mayo Clinic

    RECRUITING

    Phoenix, Arizona, 85054-4502, United States

  • Mayo Clinic

    RECRUITING

    Jacksonville, Florida, 32224, United States

  • Mayo Clinic

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • New york cancer and blood specialists - Oncology

    RECRUITING

    Port Jefferson Station, New York, 11776, United States

  • New york cancer and blood specialists - Oncology

    RECRUITING

    Port Jefferson Station, New York, 11776, United States

  • Perlmutter Cancer Center at NYU Langone Hospital Long Island

    RECRUITING

    Mineola, New York, 11501, United States

  • Rocky Mountain Cancer Centers, LLP - Oncology

    RECRUITING

    Lone Tree, Colorado, 80124, United States

  • Rutgers Cancer Institute of New Jersey

    RECRUITING

    New Brunswick, New Jersey, 08901, United States

  • Sarah Cannon Research Institute at Florida Cancer Specialists

    RECRUITING

    Orlando, Florida, 32827, United States

  • South Texas Accelerated Research Therapeutics

    RECRUITING

    San Antonio, Texas, 78229, United States

  • Texas Oncology - DFW

    RECRUITING

    Fort Worth, Texas, 76104, United States

  • Texas Oncology, P.A. - Oncology

    RECRUITING

    Tyler, Texas, 78503, United States

  • The Cancer & Hematology Centers

    RECRUITING

    Grand Rapids, Michigan, 49546, United States

  • University of North Carolina

    RECRUITING

    Chapel Hill, North Carolina, 27599, United States

  • University of North Carolina - Gastroenterology and Hepatology

    RECRUITING

    Chapel Hill, North Carolina, 27599, United States

  • Ut Southwestern

    RECRUITING

    Dallas, Texas, 75235, United States

  • Vanderbilt - Ingram Cancer Center

    RECRUITING

    Nashville, Tennessee, 37232-5505, United States

  • Virginia Cancer Specialists, PC

    RECRUITING

    Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.